Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Henlius Biotech (2696 HK)
Watchlist
70
Analysis
Health Care
•
China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
02 Jan 2023 08:55
China Healthcare Weekly (Jan.1) - NRDL Negotiation Turnaround, Pullback of TCM, Biotech Sales System
This year's NRDL negotiation could be “a landmark event” for innovative drug industry.Pullback of TCM may really begin from 23Q2.We analyzed...
Xinyao (Criss) Wang
Follow
420 Views
Share
bearish
•
Shandong BoAn Biotechnology
•
20 Dec 2022 10:00
Pre-IPO Shandong Boan Biotechnology - Conservative About the Outlook
Due to lack of differentiated/frontier enough target layout and slow progress, Boan's product commercialization potential is highly uncertain....
Xinyao (Criss) Wang
Follow
476 Views
Share
bearish
•
3D Medicines
•
02 Dec 2022 11:06
Pre-IPO 3D Medicines (3DM HK) - Some Points Worth the Attention; Our Thoughts on Valuation
The overall quality/core competitiveness of 3D Medicines isn't high. Its pipeline is mainly based on license-in model, which is not favored by Mr....
Xinyao (Criss) Wang
Follow
425 Views
Share
bearish
•
Wuxi Biologics
•
27 Nov 2022 09:03
China Healthcare Weekly (Nov25)-Wuxi Biologics, Valuation Logic Changed by NRDL, Biotech Model Fails
NRDL negotiation completely changes the valuation logic of innovative drug. We've some concerns about WuXi Bio's new business updates. The model...
Xinyao (Criss) Wang
Follow
367 Views
Share
bearish
•
Wuxi Biologics
•
11 Oct 2022 08:39
Wuxi Biologics (2269.HK) - Removed from UVL, but the Crisis Is Not Over
Removal from UVL won’t bring fundamental change.The logic of CXO(low labor cost+booming US pharmaceutical IPO) is untenable.We provide trading...
Xinyao (Criss) Wang
Follow
273 Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.32.0
x